Crossmark

Novel 5,6-dichlorobenzimidazole derivatives as dual BRAFWT and BRAFV600E inhibitors: design, synthesis, anti-cancer activity and molecular dynamics simulations

Crossref DOI link: https://doi.org/10.1186/s13065-025-01402-8

Published Online: 2025-02-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Temirak, Ahmed

El Kerdawy, Ahmed M.

Nageeb, Amira M.

Abdel-Mohsen, Heba T.
Funding

Funding for this research was provided by:

National Research Centre Egypt
License Information

Text and Data Mining valid from 2025-02-21

Version of Record valid from 2025-02-21
More Information

Article History

Received: 5 October 2024

Accepted: 28 January 2025

First Online: 21 February 2025

Declarations

:

: Egyptian National Research Centre Medical Research Ethics Committee (Approval number 315062023).

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below